In:
Obstetrical & Gynecological Survey, Ovid Technologies (Wolters Kluwer Health), Vol. 77, No. 4 ( 2022-4), p. 216-218
Abstract:
(Abstracted from N Engl J Med 2021;385:2123–2131) Standard of care treatment for advanced ovarian cancer involves primary macroscopic resection of all tumor followed by platinum-based combination chemotherapy with or without additional systemic therapy including bevacizumab or a poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor. The Descriptive Evaluation of Preoperative Selection Criteria for Operability in Recurrent Ovarian Cancer (DESKTOP) series aims to assess the role of surgery in management of recurrent ovarian cancer.
Type of Medium:
Online Resource
ISSN:
1533-9866
,
0029-7828
DOI:
10.1097/01.ogx.0000824536.49876.91
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2022
detail.hit.zdb_id:
2043471-6